Literature DB >> 33799952

Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer.

Seung Wan Son1, Mun Gyu Song1, Ba Da Yun1, Jong Kook Park1.   

Abstract

Therapeutic resistance is an inevitable impediment towards effective cancer therapies. Evidence accumulated has shown that the signaling pathways and related factors are fundamentally responsible for therapeutic resistance via regulating diverse cellular events, such as epithelial-to-mesenchymal transition (EMT), stemness, cell survival/apoptosis, autophagy, etcetera. Noncoding RNAs (ncRNAs) have been identified as essential cellular components in gene regulation. The expression of ncRNAs is altered in cancer, and dysregulated ncRNAs participate in gene regulatory networks in pathological contexts. An in-depth understanding of molecular mechanisms underlying the modulation of therapeutic resistance is required to refine therapeutic benefits. This review presents an overview of the recent evidence concerning the role of human ncRNAs in therapeutic resistance, together with the feasibility of ncRNAs as therapeutic targets in pancreatic cancer.

Entities:  

Keywords:  circular RNA; long noncoding RNA; microRNA; noncoding RNA; pancreatic cancer; therapeutic resistance

Year:  2021        PMID： 33799952      PMCID： PMC7998345          DOI： 10.3390/biomedicines9030263

Source DB:  PubMed          Journal:  Biomedicines        ISSN： 2227-9059


  236 in total

1.  Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

Authors:  Yupei Zhao; Songjie Shen; Junchao Guo; Herbert Chen; David Yu Greenblatt; Jörg Kleeff; Quan Liao; Ge Chen; Helmut Friess; Po Sing Leung
Journal:  J Surg Res       Date:  2006-10-19       Impact factor: 2.192

2.  Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.

Authors:  Jingjing Gong; Amanda R Muñoz; Subramanya Pingali; Florastina Payton-Stewart; Daniel E Chan; James W Freeman; Rita Ghosh; Addanki P Kumar
Journal:  Mol Carcinog       Date:  2016-05-25       Impact factor: 4.784

3.  MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells.

Authors:  Peng Wang; Juan Zhang; Li Zhang; Zhengfei Zhu; Jie Fan; Lianyu Chen; Liping Zhuang; Jianmin Luo; Hao Chen; Luming Liu; Zhen Chen; Zhiqiang Meng
Journal:  Gastroenterology       Date:  2013-08-02       Impact factor: 22.682

4.  Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.

Authors:  Jia Ma; Fanpeng Zeng; Cong Ma; Haijie Pang; Binbin Fang; Chaoqun Lian; Bin Yin; Xueping Zhang; Zhiwei Wang; Jun Xia
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

5.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Authors:  Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der
Journal:  Nat Med       Date:  2019-03-04       Impact factor: 53.440

6.  Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.

Authors:  Liangjing Zhou; Shengnan Jia; Guoping Ding; Mingjie Zhang; Weihua Yu; Zhengrong Wu; Liping Cao
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

7.  CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7.

Authors:  Kaixuan Zeng; Xiaoxiang Chen; Mu Xu; Xiangxiang Liu; Xiuxiu Hu; Tao Xu; Huiling Sun; Yuqin Pan; Bangshun He; Shukui Wang
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

8.  The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation.

Authors:  Qiuliang Yan; Dandan Hu; Maolan Li; Yan Chen; Xiangsong Wu; Qinghuang Ye; Zhijiang Wang; Lingzhe He; Jinhui Zhu
Journal:  Front Bioeng Biotechnol       Date:  2020-04-29

9.  A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.

Authors:  Qingcai Meng; Chen Liang; Jie Hua; Bo Zhang; Jiang Liu; Yiyin Zhang; Miaoyan Wei; Xianjun Yu; Jin Xu; Si Shi
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

Review 10.  Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions.

Authors:  Maximilian Brunner; Zhiyuan Wu; Christian Krautz; Christian Pilarsky; Robert Grützmann; Georg F Weber
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923
View more
  4 in total

Review 1.  Non-coding RNAs associated with autophagy and their regulatory role in cancer therapeutics.

Authors:  Surbhi Kumari Barnwal; Hrushikesh Bendale; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-05-10       Impact factor: 2.742

2.  CircSEC24A upregulates TGFBR2 expression to accelerate pancreatic cancer proliferation and migration via sponging to miR-606.

Authors:  Yankun Chen; Simiao Xu; Xinyuan Liu; Xueyi Jiang; Jianxin Jiang
Journal:  Cancer Cell Int       Date:  2021-12-14       Impact factor: 5.722

Review 3.  The Hypoxia-Long Noncoding RNA Interaction in Solid Cancers.

Authors:  Seung Wan Son; Ba Da Yun; Mun Gyu Song; Jin Kyeong Lee; Soo Young Choi; Hyo Jeong Kuh; Jong Kook Park
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

Review 4.  Oncogenic Role of Exosomal Circular and Long Noncoding RNAs in Gastrointestinal Cancers.

Authors:  Ba Da Yun; Ye Ji Choi; Seung Wan Son; Gabriel Adelman Cipolla; Fernanda Costa Brandão Berti; Danielle Malheiros; Tae-Jin Oh; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.